These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 37750101)

  • 1. Corrigendum to: Clinical utility of whole-genome DNA methylation profiling as a primary molecular diagnostic assay for central nervous system tumors-A prospective study and guidelines for clinical testing.
    Neurooncol Adv; 2023; 5(1):vdad114. PubMed ID: 37750101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical utility of whole-genome DNA methylation profiling as a primary molecular diagnostic assay for central nervous system tumors-A prospective study and guidelines for clinical testing.
    Galbraith K; Vasudevaraja V; Serrano J; Shen G; Tran I; Abdallat N; Wen M; Patel S; Movahed-Ezazi M; Faustin A; Spino-Keeton M; Roberts LG; Maloku E; Drexler SA; Liechty BL; Pisapia D; Krasnozhen-Ratush O; Rosenblum M; Shroff S; Boué DR; Davidson C; Mao Q; Suchi M; North P; Hopp A; Segura A; Jarzembowski JA; Parsons L; Johnson MD; Mobley B; Samore W; McGuone D; Gopal PP; Canoll PD; Horbinski C; Fullmer JM; Farooqui MS; Gokden M; Wadhwani NR; Richardson TE; Umphlett M; Tsankova NM; DeWitt JC; Sen C; Placantonakis DG; Pacione D; Wisoff JH; Teresa Hidalgo E; Harter D; William CM; Cordova C; Kurz SC; Barbaro M; Orringer DA; Karajannis MA; Sulman EP; Gardner SL; Zagzag D; Tsirigos A; Allen JC; Golfinos JG; Snuderl M
    Neurooncol Adv; 2023; 5(1):vdad076. PubMed ID: 37476329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of genome-wide DNA methylation profiling for pediatric-type diffuse gliomas.
    Otani Y; Satomi K; Suruga Y; Ishida J; Fujii K; Ichimura K; Date I
    Brain Tumor Pathol; 2023 Apr; 40(2):56-65. PubMed ID: 37004583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erratum: This is a corrigendum to: Kumthekar et al, A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma, Neuro-Oncology Advances, Volume 4, Issue 1, January-December 2022, vdac123, https://doi.org/10.1093/noajnl/vdac123.
    Neurooncol Adv; 2023; 5(1):vdad103. PubMed ID: 37664526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The case for DNA methylation based molecular profiling to improve diagnostic accuracy for central nervous system embryonal tumors (not otherwise specified) in adults.
    Halliday GC; Junckerstorff RC; Bentel JM; Miles A; Jones DTW; Hovestadt V; Capper D; Endersby R; Cole CH; van Hagen T; Gottardo NG
    J Clin Neurosci; 2018 Jan; 47():163-167. PubMed ID: 28993028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated Genomic Classification of Melanocytic Tumors of the Central Nervous System Using Mutation Analysis, Copy Number Alterations, and DNA Methylation Profiling.
    Griewank KG; Koelsche C; van de Nes JAP; Schrimpf D; Gessi M; Möller I; Sucker A; Scolyer RA; Buckland ME; Murali R; Pietsch T; von Deimling A; Schadendorf D
    Clin Cancer Res; 2018 Sep; 24(18):4494-4504. PubMed ID: 29891723
    [No Abstract]   [Full Text] [Related]  

  • 7. Validation of Whole Genome Methylation Profiling Classifier for Central Nervous System Tumors.
    Santana-Santos L; Kam KL; Dittmann D; De Vito S; McCord M; Jamshidi P; Fowler H; Wang X; Aalsburg AM; Brat DJ; Horbinski C; Jennings LJ
    J Mol Diagn; 2022 Aug; 24(8):924-934. PubMed ID: 35605901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corrigendum to: Impact of extent of resection on outcome from glioblastoma using the RANO resect group classification system: a retrospective, population-based cohort study.
    Neurooncol Adv; 2023; 5(1):vdad155. PubMed ID: 38077211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corrigendum to: Molecular alterations associated with improved outcome in patients with glioblastoma treated with Tumor-Treating Fields.
    Neurooncol Adv; 2022; 4(1):vdac164. PubMed ID: 36325375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corrigendum to: Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG 08.02) randomized clinical trial.
    Song AJ; Ding K; Alnahhas I; Laperriere NJ; Perry J; Mason WP; Winch C; O'Callaghan CJ; Menten JJ; Brandes AA; Phillips C; Fay MF; Nishikawa R; Osoba D; Cairncross JG; Roa W; Wick W; Shi W
    Neurooncol Adv; 2022; 4(1):vdac011. PubMed ID: 35098127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Corrigendum to: A phase II study of laser interstitial thermal therapy combined with doxorubicin in patients with recurrent glioblastoma.
    Butt OH; Zhou AY; Huang J; Leidig WA; Silberstein AE; Chheda MG; Johanns TM; Ansstas G; Liu J; Talcott G; Nakiwala R; Shimony JS; Kim AH; Leuthardt EC; Tran DD; Campian JL
    Neurooncol Adv; 2022; 4(1):vdac042. PubMed ID: 35505674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corrigendum to: Epigenetic dysregulation in meningiomas.
    Neurooncol Adv; 2023; 5(1):vdac190. PubMed ID: 36632569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corrigendum: Blood-Based DNA Methylation Biomarkers for Type 2 Diabetes: Potential for Clinical Applications.
    Willmer T; Johnson R; Louw J; Pheiffer C
    Front Endocrinol (Lausanne); 2019; 10():1. PubMed ID: 30723457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The central nervous system tumor methylation classifier changes neuro-oncology practice for challenging brain tumor diagnoses and directly impacts patient care.
    Karimi S; Zuccato JA; Mamatjan Y; Mansouri S; Suppiah S; Nassiri F; Diamandis P; Munoz DG; Aldape KD; Zadeh G
    Clin Epigenetics; 2019 Dec; 11(1):185. PubMed ID: 31806041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of multimodality molecular profiling for pediatric patients with central nervous system tumors.
    Rajappa P; Eng KW; Bareja R; Bander ED; Yuan M; Dua A; Bhanu Maachani U; Snuderl M; Pan H; Zhang T; Tosi U; Ivasyk I; Souweidane MM; Elemento O; Sboner A; Greenfield JP; Pisapia DJ
    Neurooncol Adv; 2022; 4(1):vdac031. PubMed ID: 35475276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corrigendum to: Generation of immunocompetent syngeneic allograft mouse models for pediatric diffuse midline glioma.
    Neurooncol Adv; 2023; 5(1):vdad072. PubMed ID: 37303863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corrigendum to: Leveraging the CSF proteome toward minimally-invasive diagnostics surveillance of brain malignancies.
    Neurooncol Adv; 2023; 5(1):vdad019. PubMed ID: 36923271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corrigendum to: Generation of chromosome 1p/19q co-deletion by CRISPR/Cas9-guided genomic editing.
    Neurooncol Adv; 2023; 5(1):vdad005. PubMed ID: 36660081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corrigendum to: ABCB1 inhibition provides a novel therapeutic target to block TWIST1-induced migration in medulloblastoma.
    Nasir A; Cardall A; Othman RT; Nicolaou N; Lourdusamy A; Linke F; Onion D; Ryzhova M; Cameron H; Valente C; Ritchie A; Korshunov A; Pfister SM; Grabowska AM; Kerr ID; Coyle B
    Neurooncol Adv; 2021; 3(1):vdab155. PubMed ID: 34988447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corrigendum: A genome-wide investigation of effects of aberrant DNA methylation on the usage of alternative promoters in hepatocellular carcinoma.
    Dong Y; Liu X; Jiang B; Wei S; Xiang B; Liao R; Wang Q; He X
    Front Oncol; 2023; 13():1253552. PubMed ID: 37719011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.